Ensysce Biosciences, Inc. (ENSC)

Market Cap	12.83M
Revenue (ttm)	4.42M
Net Income (ttm)	-7.93M
Shares Out	19.57M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,153,079
Open	0.694
Previous Close	0.678
Day's Range	0.641 - 0.694
52-Week Range	0.141 - 2.060
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: ENSC
• Website: https://www.ensysce.com

Financial Performance

In 2023, Ensysce Biosciences's revenue was $2.23 million, a decrease of -11.61% compared to the previous year's $2.52 million. Losses were -$10.63 million, -57.64% less than in 2022.